Boardroom Alpha
Boardroom Alpha
WST · Additional Proxy Materials (DEFA14A) · Filed March 12, 2026

West Pharmaceutical Services Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 12, 2026
Ticker
WST
Accession
0001104659-26-026779
Boardroom Alpha · Filing insights

West Pharmaceutical Services' definitive materials urge voting for all directors, advisory pay, and auditor ratification. The board opposes the independent Board Chair policy proposal.

About West Pharmaceutical Services Inc
Market cap
$22.1B
1Y TSR
+43.0%
3Y TSR
−4.2%
Board grade
B
Sector
Healthcare
CEO
Michel Lagarde
Last annual meeting: May 4, 2026 · View full West Pharmaceutical Services Inc profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No.           )

Filed by the Registrant   x

Filed by a Party other than the Registrant  ¨

Check the appropriate box:

¨

Preliminary Proxy Statement

¨

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨

Definitive Proxy Statement

x

Definitive Additional Materials

¨

Soliciting Material under §240.14a-12

  

 

West Pharmaceutical Services, Inc.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x

No fee required.

¨

Fee paid previously with preliminary materials.

¨

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11


GRAPHIC

Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V88228-P45265 WEST PHARMACEUTICAL SERVICES, INC. 2026 Annual Meeting Vote by May 3, 2026 11:59 P.M. EDT. For shares held in a Plan, vote by April 30, 2026 11:59 P.M. EDT. WEST PHARMACEUTICAL SERVICES, INC. C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS P.O. BOX 1342 BRENTWOOD, NY 11717 You invested in WEST PHARMACEUTICAL SERVICES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 4, 2026. Vote Virtually at the Meeting* May 4, 2026 9:30 AM EDT Virtually at: www.virtualshareholdermeeting.com/WST2026 Get informed before you vote View the Notice and Proxy Statement and 2025 Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 20, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote. com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

GRAPHIC

THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V88229-P45265 1. Election of Directors Nominees: 1a. Mark A. Buthman For 1b. William F. Feehery For 1c. Robert F. Friel For 1d. Eric M. Green For 1e. Janet B. Haugen For 1f. Molly E. Joseph For 1g. Deborah L. V. Keller For 1h. Myla P. Lai-Goldman For 1i. Stephen H. Lockhart For 1j. Douglas A. Michels For 1k. Paolo Pucci For 2. Advisory vote to approve named executive officer compensation. For 3. Ratification of the appointment of our independent registered public accounting firm for 2026. For 4. Shareholder proposal regarding an independent Board Chair policy. Against NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from West Pharmaceutical Services Inc (WST)

Reference

Frequently asked questions

When did West Pharmaceutical Services Inc file this DEFA14A?
West Pharmaceutical Services Inc (WST) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 12, 2026. The accession number assigned by EDGAR is 0001104659-26-026779.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
West Pharmaceutical Services' definitive materials urge voting for all directors, advisory pay, and auditor ratification. The board opposes the independent Board Chair policy proposal. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find West Pharmaceutical Services Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A West Pharmaceutical Services Inc has filed under CIK 105770, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer